View ValuationPeptiDream 향후 성장Future 기준 점검 0/6PeptiDream (는) 각각 연간 1.8% 및 3.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 1.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 19% 로 예상됩니다.핵심 정보1.8%이익 성장률1.75%EPS 성장률Biotechs 이익 성장0%매출 성장률3.4%향후 자기자본이익률18.97%애널리스트 커버리지Good마지막 업데이트16 Jan 2025최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 21PeptiDream Inc. Announces Initiation Of Phase 1 Clinical Trial Of AK1940 by its Collaboration Partner Asahi Kasei TherapeuticsPeptiDream Inc. announced that Asahi Kasei Therapeutics its collaboration partner, has initiated a Phase 1 clinical trial1 of “AK1940”, a selective inhibitor of TNF receptor 1 (“TNFR1”). AK1940 is a macrocyclic peptide discovered through a research collaboration between the two companies using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS®)2. AK1940 showed potent inhibitory activity and high selectivity for TNFR1 and exhibited efficacy in animal models of inflammatory disease, supporting its potential for the treatment of a broad range of autoimmune diseases. PeptiDream and Asahi Kasei Therapeutics entered into a collaborative research and development agreement in March 2016, under which the two companies have advanced the discovery of macrocyclic peptides using PeptiDream’s PDPS® technology. Asahi Kasei Therapeutics focuses its drug discovery and development efforts on disease areas including autoimmune diseases, severe infections, transplantation, kidney diseases, and orthopedic conditions. AK1940 is well aligned with Asahi Kasei Therapeutics’ R&D strategy and is expected to contribute to the medium- to long-term growth of the company’s pharmaceuticals business. With the initiation of the Phase 1 trial, PeptiDream will receive a milestone payment (amount undisclosed). Furthermore, PeptiDream is entitled to receive future clinical milestone payments, as well as royalties based on sales after launch.공시 • Mar 23PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)공시 • Feb 16+ 1 more updatePeptiDream Inc., Annual General Meeting, Mar 25, 2026PeptiDream Inc., Annual General Meeting, Mar 25, 2026.공시 • Dec 18PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of PsoriasisPeptiDream Inc. announced its second oral peptide therapeutic program entering into its Clinical Development Portfolio - a dual IL-17A and IL-17F macrocyclic peptide inhibitor targeting the major dimeric forms of interleukin-17 (IL-17AA, IL-17AF, IL-17FF) - at their 2025 R&D Day held on December 5, 2025. The development candidate demonstrated biologic-like efficacy in preclinical models when orally administered, aiming to deliver a deeper and more durable response across skin and musculoskeletal manifestations, improving patient quality of life. The IL17 pathway is a clinically validated therapeutic target across several major autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Although today's approved IL17 inhibitors deliver excellent clinical outcomes, all are injectable biologics, which can limit convenience and long-term accessibility. PeptiDream's oral IL17 macrocyclic peptide is designed to change this paradigm--offering the potential for biologiclike efficacy with the benefits of oral administration, as well as the versatility for monotherapy or combination therapy with TNF or JAK inhibitors, providing new options for patients with difficulttotreat disease. Key Highlights of the Program: Potent Orally Bioavailable Macrocyclic Peptide: Engineered for high-affinity and stability to achieve oral bioavailability and biologic-like potency. Inhibits Critical IL-17 Isoforms: Designed to inhibit not only IL-17A/A, IL-17A/F, but also IL-17F/F, associated with deeper and more durable clinical responses. Enhanced Tissue Penetration: The macrocyclic peptide candidate's small size enables improved distribution and potential for superior tissue-localized activity. Broad Therapeutic Opportunity: An oral therapy with the potential to treat a broad range of IL17-mediated diseases, unlocking new monotherapy and combination therapy approaches. PeptiDream's Oral dual IL-17A andIL-17F inhibitor was discovered using its proprietary PDPS®? technology and optimized for potency and oral bioavailability. In an IL-17 in vivo challenge model, oral dosing of peptide significantly reduced CXCL1 levels to the same extent as IV administration of an approved IL-17 biologic. Notably, greater skin distribution versus plasma was observed at 24 hours--a key differentiator over current biologics. Building on these encouraging results, PeptiDream is advancing the program into IND-enabling studies with a view toward clinical trials, while exploring strategic partnerships to accelerate global development and deliver a best-in-class oral therapy for autoimmune disease patients worldwide.공시 • Dec 03PeptiDream Inc. to Report Fiscal Year 2025 Results on Feb 16, 2026PeptiDream Inc. announced that they will report fiscal year 2025 results on Feb 16, 2026공시 • Oct 15PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA- I&T for Prostate Cancer in JapanPeptiDream Inc., PDRadiopharma Inc. and Curium Group announced that a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. 64Cu-PSMA- I&T is being assessed as a diagnostic PET imaging agent labeled with the radioisotope Copper-64, being developed with its therapeutic pair, 177Lu-PSMA-I &T. The development is conducted under the strategic collaboration between PDRadiopharma and Curium aiming at advancing innovative radiopharmaceuticals for prostate cancer in Japan. The open-label, single-arm Phase 2 study will evaluate the sensitivity, specificity, and safety of 64Cu-PSMA- me&T. The trial will enroll approximately 70 patients who have been newly diagnosed with unfavorable intermediate, high or very high-risk prostate cancer and are scheduled for prostatectomy with pelvic lymph node dissection. This study is being conducted as a registrational trial in Japan and will utilize bridging data from Curium's ongoing global clinical trials. In parallel, a clinical trial for 177Lu-PSMA- I& T as a therapeutic agent is being planned to evaluate its efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).공시 • Sep 27PeptiDream Inc. to Report Q3, 2025 Results on Nov 12, 2025PeptiDream Inc. announced that they will report Q3, 2025 results on Nov 12, 2025공시 • May 31PeptiDream Inc. to Report Q2, 2025 Results on Aug 06, 2025PeptiDream Inc. announced that they will report Q2, 2025 results on Aug 06, 2025공시 • Mar 30National Cancer Center Hospital East and PeptiDream Inc. Announces New Radiopharmaceuticals for Renal Cell CarcinomaNational Cancer Center Hospital East and PeptiDream Inc. announced promising results from the first-in-human imaging trial of 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CA9), for patients with clear cell renal cell carcinoma (ccRCC). This trial, which was conducted at the NCC Hospital East in collaboration started from November 2023, aims for the early application of radiopharmaceuticals targeting CA9. The results showed that 64Cu-PD-327 66 effectively diagnosed tumors and in addition, calculations replacing 64Cu with 225Ac suggest that the absorbed dose in the tumor was 105.5+-55.8 mGy/MBq, which is expected to be sufficient for therapeutic effect. These findings were presented at the ASCO Genitourinary Cancers Symposium 2025 held in February 2025. In this trial, Cu-PD-32766, which was manufactured using NCC Hospital’s Cu production technologies and EPOC’s radiopharmaceuticals manufacturing technologies, was administered to five patients with newly diagnosed, relapsed or suspected relapsed ccRCC at NCC Hospital East. The safety, pharmacokinetics and dosimetry of PET/CT imaging using Cu-PD-32766 were evaluated. The effective dose for whole body by administration of Cu-PD-32766 was 0.102±0.0361 mSv/MBq and no serious side effects or adverse events were observed. Accumulation of Cu-PD-32766 in tumor lesions was confirmed by PET imaging within 5 minutes after administration, with positive rate of over 95% of lesions diagnosed by CT imaging. Clear PET images of tumor lesions were obtained from 5 minutes to 24 hours post-administration. The blood concentration of Cu-PD-32766 rapidly decreased within 5 minutes after administration, confirming good clearance. These results suggest the potential utility of Cu-PD-32766 as a diagnostic agent for ccRCC. Furthermore, calculations replacing Cu with the therapeutic radionuclide Ac suggest that the absorbed dose in the tumor was 105.5±55.8 mGy/MBq, which is expected to be sufficient for therapeutic effects. This trial investigated the potential application of Cu-PD-32766 as a diagnostic agent by evaluating safety, pharmacokinetics and whole-body absorbed dose. The results also suggest the potential theranostic application of PD-32766 by using both diagnostic and therapeutic radionuclides such as Ac. By evaluating the pharmacokinetics and targeted accumulation in tumors with a minimal dose administered to patients, this trial is anticipated to contribute to accelerating subsequent clinical development of PD-32766. CA9 is a cell surface antigen highly expressed in ~95% of ccRCC with minimal expression in normal tissues, making it a potentially ideal target for the diagnosis and treatment of ccRCC. PeptiDream discovered and developed PD-32766 using its proprietary Peptide Discovery Platform System (PDPS) technology, with in vivo imaging and efficacy studies conducted by PDRadiopharma Inc., PeptiDream’s wholly owned subsidiary.공시 • Feb 13PeptiDream Inc., Annual General Meeting, Mar 27, 2025PeptiDream Inc., Annual General Meeting, Mar 27, 2025.공시 • Dec 12PeptiDream Inc. Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric CancerPeptiDream Inc. announced its second wholly-owned radiopharmaceutical development candidate arising from the company's ongoing internal peptide radiopharmaceutical discovery and development efforts. The development candidate ("PD-29875") is a novel first-in-class highly-selective macrocyclic peptide-radioisotope (RI) conjugate against Claudin 18.2 ("CLDN18.2"), a member of the claudin family of proteins that are integral components of tight junctions found in epithelial tissues. CLDN18.2 is expressed in a variety of solid tumors, including gastric cancer, pancreatic cancer, biliary cancer, genitourinary tract cancers, and colorectal cancer, and others. PD-29875 was discovered using PeptiDream's proprietary PDPS technology and further optimized at PeptiDream with in vivo imaging and efficacy studies conducted at PDRadiopharma, wholly owned subsidiary. PeptiDream has initiated IND-enabling studies of PD-29875 and intends to initially develop the therapeutic (225Ac-PD-29875) and paired diagnostic imaging agent (64Cu-PD-29875) for the diagnosis and treatment of gastric cancer. The paired diagnostic imaging agent, which consists of the same peptide and chelator as the therapeutic, will enable to screen and identify patients, both in clinical trials and in clinical practice, who have CLDN18.2 expressing tumors that are most likely to have a favorable clinical response from PD-29875 treatment. PeptiDream is previously planning to initiate human Ph0 imaging studies of 64Cu-PD-29875 in 2025, prior to the start of a Phase 1 study. Gastric cancer is the 5th most common cancer in and the 4th leading cause of cancer death worldwide in 2020, representing 7% of all global cancer diagnoses, with an approximate 5-year survival rate of 32% (worldwide an estimated 1.1 million people were diagnosed with gastric cancer in 2020, with 770,000 deaths), with the incidence expected to increase to 1.8 million new cases per year by 2040.공시 • Dec 03PeptiDream Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025PeptiDream Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025공시 • Nov 12PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd.PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024. PeptiDream Inc. (TSE:4587) completed the acquisition of an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024.이익 및 매출 성장 예측BMV:4587 N - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202749,40315,48515,98914,770412/31/202643,51311,86014,37113,197812/31/202540,26310,71413,84213,280812/31/202447,81417,22717,10510,07089/30/202447,77317,11525,06827,078N/A6/30/202455,41921,689-780992N/A3/31/202427,9742,4411,2282,760N/A12/31/202328,7123,03511,05212,420N/A9/30/202338,18711,2819,21310,512N/A6/30/202331,2547,9567,3978,696N/A3/31/202331,3968,1353,7487,663N/A12/31/202226,8527,554-4,057-82N/A9/30/202212,81157-5,082-1,376N/A6/30/202211,5111,705-2,4831,687N/A3/31/20228,3262,3414211,929N/A12/31/20219,3663,6065,4406,655N/A9/30/202115,6077,1105,2296,447N/A6/30/202111,4494,3294,8695,368N/A3/31/202112,7435,2265,6436,111N/A12/31/202011,6774,4481,1461,733N/A12/31/20192,075-977207484N/A6/30/20197,2172,7704,2864,481N/A6/30/20186,4272,335N/A1,023N/A3/31/20184,616895N/A623N/A9/30/20174,271962N/A517N/A6/30/20174,8961,891N/A1,531N/A3/31/20173,064769N/A1,095N/A12/31/20164,4571,685N/A2,338N/A9/30/20164,7351,823N/A2,844N/A6/30/20164,3281,581N/A1,533N/A3/31/20164,6201,976N/A2,027N/A12/31/20153,1211,203N/A1,216N/A9/30/20152,7221,063N/A834N/A6/30/20152,4741,004N/A1,386N/A3/31/201575746N/A85N/A12/31/201473967N/A74N/A9/30/2014786118N/A165N/A6/30/2014819149N/A72N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 4587 N 의 연간 예상 수익 증가율(1.8%)이 saving rate(8.1%) 미만입니다.수익 vs 시장: 4587 N 의 연간 수익(1.8%)이 MX 시장(9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 4587 N 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 4587 N 의 수익(연간 3.4%)이 MX 시장(연간 6.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 4587 N 의 수익(연간 3.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 4587 N의 자본 수익률은 3년 후 19%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/02/02 16:42종가2024/11/05 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PeptiDream Inc.는 14명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Shan HeBernsteinHidemaru YamaguchiCitigroup IncKazuaki HashiguchiDaiwa Securities Co. Ltd.11명의 분석가 더 보기
공시 • Apr 21PeptiDream Inc. Announces Initiation Of Phase 1 Clinical Trial Of AK1940 by its Collaboration Partner Asahi Kasei TherapeuticsPeptiDream Inc. announced that Asahi Kasei Therapeutics its collaboration partner, has initiated a Phase 1 clinical trial1 of “AK1940”, a selective inhibitor of TNF receptor 1 (“TNFR1”). AK1940 is a macrocyclic peptide discovered through a research collaboration between the two companies using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS®)2. AK1940 showed potent inhibitory activity and high selectivity for TNFR1 and exhibited efficacy in animal models of inflammatory disease, supporting its potential for the treatment of a broad range of autoimmune diseases. PeptiDream and Asahi Kasei Therapeutics entered into a collaborative research and development agreement in March 2016, under which the two companies have advanced the discovery of macrocyclic peptides using PeptiDream’s PDPS® technology. Asahi Kasei Therapeutics focuses its drug discovery and development efforts on disease areas including autoimmune diseases, severe infections, transplantation, kidney diseases, and orthopedic conditions. AK1940 is well aligned with Asahi Kasei Therapeutics’ R&D strategy and is expected to contribute to the medium- to long-term growth of the company’s pharmaceuticals business. With the initiation of the Phase 1 trial, PeptiDream will receive a milestone payment (amount undisclosed). Furthermore, PeptiDream is entitled to receive future clinical milestone payments, as well as royalties based on sales after launch.
공시 • Mar 23PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD)
공시 • Feb 16+ 1 more updatePeptiDream Inc., Annual General Meeting, Mar 25, 2026PeptiDream Inc., Annual General Meeting, Mar 25, 2026.
공시 • Dec 18PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of PsoriasisPeptiDream Inc. announced its second oral peptide therapeutic program entering into its Clinical Development Portfolio - a dual IL-17A and IL-17F macrocyclic peptide inhibitor targeting the major dimeric forms of interleukin-17 (IL-17AA, IL-17AF, IL-17FF) - at their 2025 R&D Day held on December 5, 2025. The development candidate demonstrated biologic-like efficacy in preclinical models when orally administered, aiming to deliver a deeper and more durable response across skin and musculoskeletal manifestations, improving patient quality of life. The IL17 pathway is a clinically validated therapeutic target across several major autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Although today's approved IL17 inhibitors deliver excellent clinical outcomes, all are injectable biologics, which can limit convenience and long-term accessibility. PeptiDream's oral IL17 macrocyclic peptide is designed to change this paradigm--offering the potential for biologiclike efficacy with the benefits of oral administration, as well as the versatility for monotherapy or combination therapy with TNF or JAK inhibitors, providing new options for patients with difficulttotreat disease. Key Highlights of the Program: Potent Orally Bioavailable Macrocyclic Peptide: Engineered for high-affinity and stability to achieve oral bioavailability and biologic-like potency. Inhibits Critical IL-17 Isoforms: Designed to inhibit not only IL-17A/A, IL-17A/F, but also IL-17F/F, associated with deeper and more durable clinical responses. Enhanced Tissue Penetration: The macrocyclic peptide candidate's small size enables improved distribution and potential for superior tissue-localized activity. Broad Therapeutic Opportunity: An oral therapy with the potential to treat a broad range of IL17-mediated diseases, unlocking new monotherapy and combination therapy approaches. PeptiDream's Oral dual IL-17A andIL-17F inhibitor was discovered using its proprietary PDPS®? technology and optimized for potency and oral bioavailability. In an IL-17 in vivo challenge model, oral dosing of peptide significantly reduced CXCL1 levels to the same extent as IV administration of an approved IL-17 biologic. Notably, greater skin distribution versus plasma was observed at 24 hours--a key differentiator over current biologics. Building on these encouraging results, PeptiDream is advancing the program into IND-enabling studies with a view toward clinical trials, while exploring strategic partnerships to accelerate global development and deliver a best-in-class oral therapy for autoimmune disease patients worldwide.
공시 • Dec 03PeptiDream Inc. to Report Fiscal Year 2025 Results on Feb 16, 2026PeptiDream Inc. announced that they will report fiscal year 2025 results on Feb 16, 2026
공시 • Oct 15PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA- I&T for Prostate Cancer in JapanPeptiDream Inc., PDRadiopharma Inc. and Curium Group announced that a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. 64Cu-PSMA- I&T is being assessed as a diagnostic PET imaging agent labeled with the radioisotope Copper-64, being developed with its therapeutic pair, 177Lu-PSMA-I &T. The development is conducted under the strategic collaboration between PDRadiopharma and Curium aiming at advancing innovative radiopharmaceuticals for prostate cancer in Japan. The open-label, single-arm Phase 2 study will evaluate the sensitivity, specificity, and safety of 64Cu-PSMA- me&T. The trial will enroll approximately 70 patients who have been newly diagnosed with unfavorable intermediate, high or very high-risk prostate cancer and are scheduled for prostatectomy with pelvic lymph node dissection. This study is being conducted as a registrational trial in Japan and will utilize bridging data from Curium's ongoing global clinical trials. In parallel, a clinical trial for 177Lu-PSMA- I& T as a therapeutic agent is being planned to evaluate its efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).
공시 • Sep 27PeptiDream Inc. to Report Q3, 2025 Results on Nov 12, 2025PeptiDream Inc. announced that they will report Q3, 2025 results on Nov 12, 2025
공시 • May 31PeptiDream Inc. to Report Q2, 2025 Results on Aug 06, 2025PeptiDream Inc. announced that they will report Q2, 2025 results on Aug 06, 2025
공시 • Mar 30National Cancer Center Hospital East and PeptiDream Inc. Announces New Radiopharmaceuticals for Renal Cell CarcinomaNational Cancer Center Hospital East and PeptiDream Inc. announced promising results from the first-in-human imaging trial of 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CA9), for patients with clear cell renal cell carcinoma (ccRCC). This trial, which was conducted at the NCC Hospital East in collaboration started from November 2023, aims for the early application of radiopharmaceuticals targeting CA9. The results showed that 64Cu-PD-327 66 effectively diagnosed tumors and in addition, calculations replacing 64Cu with 225Ac suggest that the absorbed dose in the tumor was 105.5+-55.8 mGy/MBq, which is expected to be sufficient for therapeutic effect. These findings were presented at the ASCO Genitourinary Cancers Symposium 2025 held in February 2025. In this trial, Cu-PD-32766, which was manufactured using NCC Hospital’s Cu production technologies and EPOC’s radiopharmaceuticals manufacturing technologies, was administered to five patients with newly diagnosed, relapsed or suspected relapsed ccRCC at NCC Hospital East. The safety, pharmacokinetics and dosimetry of PET/CT imaging using Cu-PD-32766 were evaluated. The effective dose for whole body by administration of Cu-PD-32766 was 0.102±0.0361 mSv/MBq and no serious side effects or adverse events were observed. Accumulation of Cu-PD-32766 in tumor lesions was confirmed by PET imaging within 5 minutes after administration, with positive rate of over 95% of lesions diagnosed by CT imaging. Clear PET images of tumor lesions were obtained from 5 minutes to 24 hours post-administration. The blood concentration of Cu-PD-32766 rapidly decreased within 5 minutes after administration, confirming good clearance. These results suggest the potential utility of Cu-PD-32766 as a diagnostic agent for ccRCC. Furthermore, calculations replacing Cu with the therapeutic radionuclide Ac suggest that the absorbed dose in the tumor was 105.5±55.8 mGy/MBq, which is expected to be sufficient for therapeutic effects. This trial investigated the potential application of Cu-PD-32766 as a diagnostic agent by evaluating safety, pharmacokinetics and whole-body absorbed dose. The results also suggest the potential theranostic application of PD-32766 by using both diagnostic and therapeutic radionuclides such as Ac. By evaluating the pharmacokinetics and targeted accumulation in tumors with a minimal dose administered to patients, this trial is anticipated to contribute to accelerating subsequent clinical development of PD-32766. CA9 is a cell surface antigen highly expressed in ~95% of ccRCC with minimal expression in normal tissues, making it a potentially ideal target for the diagnosis and treatment of ccRCC. PeptiDream discovered and developed PD-32766 using its proprietary Peptide Discovery Platform System (PDPS) technology, with in vivo imaging and efficacy studies conducted by PDRadiopharma Inc., PeptiDream’s wholly owned subsidiary.
공시 • Feb 13PeptiDream Inc., Annual General Meeting, Mar 27, 2025PeptiDream Inc., Annual General Meeting, Mar 27, 2025.
공시 • Dec 12PeptiDream Inc. Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric CancerPeptiDream Inc. announced its second wholly-owned radiopharmaceutical development candidate arising from the company's ongoing internal peptide radiopharmaceutical discovery and development efforts. The development candidate ("PD-29875") is a novel first-in-class highly-selective macrocyclic peptide-radioisotope (RI) conjugate against Claudin 18.2 ("CLDN18.2"), a member of the claudin family of proteins that are integral components of tight junctions found in epithelial tissues. CLDN18.2 is expressed in a variety of solid tumors, including gastric cancer, pancreatic cancer, biliary cancer, genitourinary tract cancers, and colorectal cancer, and others. PD-29875 was discovered using PeptiDream's proprietary PDPS technology and further optimized at PeptiDream with in vivo imaging and efficacy studies conducted at PDRadiopharma, wholly owned subsidiary. PeptiDream has initiated IND-enabling studies of PD-29875 and intends to initially develop the therapeutic (225Ac-PD-29875) and paired diagnostic imaging agent (64Cu-PD-29875) for the diagnosis and treatment of gastric cancer. The paired diagnostic imaging agent, which consists of the same peptide and chelator as the therapeutic, will enable to screen and identify patients, both in clinical trials and in clinical practice, who have CLDN18.2 expressing tumors that are most likely to have a favorable clinical response from PD-29875 treatment. PeptiDream is previously planning to initiate human Ph0 imaging studies of 64Cu-PD-29875 in 2025, prior to the start of a Phase 1 study. Gastric cancer is the 5th most common cancer in and the 4th leading cause of cancer death worldwide in 2020, representing 7% of all global cancer diagnoses, with an approximate 5-year survival rate of 32% (worldwide an estimated 1.1 million people were diagnosed with gastric cancer in 2020, with 770,000 deaths), with the incidence expected to increase to 1.8 million new cases per year by 2040.
공시 • Dec 03PeptiDream Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025PeptiDream Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025
공시 • Nov 12PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd.PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024. PeptiDream Inc. (TSE:4587) completed the acquisition of an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024.